Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides

Journal of Medicinal Chemistry

Volumn 46, Issue 3, 2003, Pages 417-426

  Nicolaou, Ioannis ^a   Demopoulos, Vassilis J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

(2 BENZOYLPYRROL 1 YL)ACETIC ACID; (3 BENZOYLPYRROL 1 YL)ACETIC ACID; [2,4 BIS(4 METHOXYBENZOYL)PYRROL 1 YL]ACETIC ACID; ACETIC ACID DERIVATIVE; ALDEHYDE REDUCTASE; EPALRESTAT; FIDARESTAT; MONOSACCHARIDE; PYRROLE DERIVATIVE; SERUM ALBUMIN; TOLRESTAT; TROLOX C; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; GLYCATION; MALE; NONHUMAN; OXIDATION; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

ACETIC ACIDS; ALDEHYDE REDUCTASE; ANIMALS; DIABETES MELLITUS; ENZYME INHIBITORS; FEMALE; FRUCTOSE; MALE; MONOSACCHARIDES; OXIDATION-REDUCTION; PROTEINS; PYRROLES; RATS; RATS, INBRED F344; SERUM ALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037472690     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0209477     Document Type: Article

References (74)

1. (a) King, H.; Aubert, R. E.; Herman, W. H. Global Burden of Diabetes, 1995-2025: Prevalence, Numeric Estimates, and Projections. Diabetes Care 1998, 21, 1414-1431.
2. (b) Haigh, D.; Avandia-From Molecule to Market for Type 2 Diabetes. Abstracts of Papers; 223rd National Meeting of the American Chemical Society, Apr 7-11, 2002, Orlando, FL; American Chemical Society: Washington, DC, 2002; 132-MEDI.
3. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes Complications and their Potential Prevention: Aldose Reductase Inhibition and other Approaches. Med. Res. Rev. 1999, 19, 3-23.
4. (a) Kangas, T.; Aro, S.; Koivisto, V. A.; Salinto, M.; Laakso, M.; Reunanen, A. Structure and Costs of Health Care of Diabetic Patients in Finland. Diabetes Care 1996, 19, 191-197.
5. (b) Parving, H. H. Strategies to Reduce the Burden of Diabetic Complications. Diabetologia 1997, 40, B9-B10.
6. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 1993, 329, 977-986.
7. (a) Okhubo, Y.; Kishikawa, H.; Araki, E.; Miyata, T.; Isami, S.; Motoyoshi, S.; Kojima, Y.; Furugoshi, N.; Shichiri, M. Intensive Insulin Therapy Prevents the Progression of Diabetic Microvascular Complications in Japanese Patients with Non-Insuline-Dependent Diabetes Mellitus: A Randomized Prospective 6-Year Study. Diabetes Res. Clin. Pract. 1995, 28, 103-117.
8. (b) American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 1998, 21, S88-90.
9. Barrett-Connor, E.; Wingard, D. L. "Normal" Blood Glucose and Coronary Risk. Br. Med. J. 2001, 322, 5-6.
10. Carrington, A. L.; Litchfield, J. E. The Aldose Reductase Pathway and Nonenzymatic Glycation in the Pathogenesis of Diabetic Neuropathy: A Critical Review for the End of the 20th Century. Diabetes Rev. 1999, 7, 275-299.
11. Stout, R. W. Insulin and Atheroma-An Update. Lancet 1987, 1 (Iss. 8541), 1077-1079.
12. Friedman, E. A. Advanced Glycosylated End Products and Hyperglycemia in the Pathogenesis of Diabetic Complications. Diabetes Care, 1999, 22 (Suppl. 2), B65-71.
13. Oates, P. J.; Mylari, B. L. Aldose Reductase Inhibitors: Therapeutic Implications for Diabetic Complications. Expert Opin. Investig. Drugs 1999, 8, 2095-2119.
14. (a) Tomlinson, D. R.; Stevens, E. J.; Diemel, L. T. Aldose Reductase Inhibitors and their Potential for the Treatment of Diabetic Complications. Trends Pharmacol. Sci. 1994, 15, 293-297.
15. (b) Nishimura, C. Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications. Pharmacol. Rev. 1998, 50, 21-33.
16. (c) Mistry, K. P.; Beyer-Mears, A.; Diecke, F. P. J. Mechanisms for D-Glucose Inhibition ofmyo-Inositol Influx into Rats Lens. Diabetes 1993, 42, 1737-1744.
17. (d) Stevens, M. J.; Lattimer, S. A.; Kamijo, M.; Van Huysen, C.; Sima, A. A. F.; Greene, D. A. Osmotically-Induced Nerve Taurine Depletion and the Compatible Osmolyte Hypothesis in Experimental Diabetic Neuropathy in the Rat. Diabetologia 1993, 36, 608-614.
18. (e) De Luca, G.; Calpona, P. R., Caponetti, A.; Romano, G.; Di Benedetto A.; Cucinotta, D.; Di Giorgio, R. M. Taurine and Osmoregulation: Platelet Taurine Content, Uptake, and Release in Type 2 Diabetic Patients. Metab.-Clin. Exp. 2001, 50, 60-64.
19. Kawasaki, Y.; Fujii, J.; Miyazawa, N.; Hoshi, A.; Okado, A.; Tano, Y.; Taniguchi, N. Specific Detections of the Early Process of the Glycation Reactions By Fructose and Glucose in Diabetic Rat Lens. FEBS Lett. 1998, 441, 116-120.
20. (a) Wolff, S. P.; Jiang, Z. Y.; Hunt, J. V. Protein Glycation and Oxidative Stress in Diabetes Mellitus and Aging. Free Radic. Biol. Med. 1991, 10, 339-352.
21. (b) Takagi, Y.; Kashiwagi, A.; Tanaka, Y.; Asahina, T.; Kikkawa, R.; Shigeta, Y. Significance of Fructose-Induced Protein Oxidation and Formation of Advanced Glycation End Product. J. Diabetes Complicat. 1995, 9, 87-91.
22. (c) Hayase, F.; Shibuya, T.; Sato, J.; Yamamoto, M. Effects of Oxygen and Transition Metals on the Advanced Maillard Reaction of Proteins with Glucose. Biosci. Biotech. Biochem. 1996, 60, 1820-1825.
23. (a) Hunt, J. V.; Wolff, S. P. Oxidative Glycation and Free Radical Production: A Causal Mechanism of Diabetic Complications. Free Rad. Res. Commun. 1991, 12-13, 115-123.
24. Constantino, L.; Rastelli, G.; Gamberini, M. C.; Vinson, J. A.; Bose, P.; Iannone, A.; Staffieri, M.; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-Benzopyran-4-one Antioxidants as Aldose Reductase Inhibitors. J. Med. Chem. 1999, 42, 1881-1893.
25. Nakamura, N.; Obayashi, H.; Fujii, M.; Fukui, M.; Yoshimori, K.; Ogata, M.; Hasegawa, G.; Shigeta, H.; Kitagawa, Y.; Yoshikawa, T.; Kondo, M.; Ohta, M.; Nishimura, M.; Nishinaka, T.; Nishimura, C. Y. Induction of Aldose Reductase in Cultured Human Microvascular Endothelial Cells by Advanced Glycation End Products. Free Radic. Biol. Med. 2000, 29, 17-25.
26. Oberley, L. W. Free Radicals and Diabetes. Free Radic. Biol. Med. 1988, 5, 113-124.
27. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Barlocco, D. Pharmacological Approaches to the Treatment of Diabetic Complications. Expert Opin. Ther. Patents 2000, 10, 1245-1262.
28. Strupczewski, J. D.; Ellis, D. B. To Market, To Market-1992. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press Inc.: San Diego, 1993; vol. 28; p 330.
29. (a) Banditelli, S.; Boldrini, E.; Vilardo, P. G.; Cecconi, I.; Cappiello, M.; dal Monte, M.; Marini I.; del Corso, A.; Mura, U. A New Approach Against Sugar Cataract Through Aldose Reductase Inhibitors. Exp. Eye Res. 1999, 69, 533-538.
30. (b) Nakamura, J.; Kasuya, Y.; Hamad, Y.; Nakshima, E.; Naruse, K.; Yasuda, Y.; Kato, K.; Hotta, N. Glucose-Induced Hyperproliferation of Cultured Rat Aortic Smooth Muscle Cells through Polyol Pathway Hyperactivity. Diabetologia 2001, 44, 480-487.
31. (c) Murata, M.; Ohta, N.; Sakurai, S.; Alam, S.; Tsai, J. Y.; Kador, P. F.; Sato, S. The Role of Aldose Reductase in Sugar Cataract Formation: Aldose Reductase Plays a Key Role in Lens Epithelial Cell Death (Apoptosis). Chem.-Biol. Interact. 2001, 130 (1-3 Special Issue S1), 617-625.
32. (a) Hamada, Y.; Nakamura, J.; Naruse, K.; Komori, T.; Kato, K.; Kasuya, Y.; Nagai, R.; Horiuchi, S.; Hotta, N. Epalrestat, an Aldose Reductase Inhibitor, Reduces the Levels of N-Epsilon-(Carboxymethyl)Lysine Protein Adducts and their Precursors in Erythrocytes from Diabetic Patients. Diabetes Care 2000, 23, 1539-1544.
33. (b) Nakayama, M.; Nakamura, J.; Hamada, J.; Chaya, S.; Mizubayashi, R.; Yasuda, Y.; Kamiya, K.; Koh, N.; Hotta, N. Aldose Reductase Inhibition Ameliorates Pupillary Light Reflex and F-Wave Latency in Patients with Mild Diabetic Neuropathy. Diabetes Care 2001, 24, 1093-1098.
34. (c) Johnson, B. F.; Law, G.; Nesto, R.; Pfeifer, M.; Slater, W.; Vinic, A.; Wackers, F.; Young, L. Aldose Reductase Inhibitor Zopolrestat Improves Systolic Function in Diabetics. Diabetes, 1999, 48 (Iss. S1), 574.
35. (d) Hotta, N.; Ishii, J.; Sakamoto, N. Effects of Fidarestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy. A 52-Week Placebo-Controlled Double-Blind-Study. Diabetes 2000, 49 (Iss. S1), 142.
36. (a) Kawabata, T.; Packer, L. Alpha-Lipoate Can Protect Against Glycation of Serum Albumin, but not Low-Density Lipoprotein. Biochem. Biophys. Res. Commun. 1994, 203, 99-104.
37. (b) Stefek, M.; Krizanova, L.; Trnkova, Z. Oxidative Modification of Serum Albumin in an Experimental Glycation Model of Diabetes Mellitus In Vitro: Effect of the Pyridoindole Antioxidant Stobadine. Life Sci. 1999, 65, 1995-1997.
38. Vinson, J. A.; Howard, T. B., III. Inhibition of Protein Glycation and Advanced Glycation End Products by Ascorbic Acid and other Nutrients. J. Nutr. Biochem. 1996, 7, 659-663.
39. Edelstein, D.; Brownlee, M. Mechanistic Studies of Advanced Glycation End Product Inhibition by Aminoguanidine. Diabetes 1992, 41, 26-29.
40. Miyata, T.; Ueda, Y.; Asahi, K.; Izuhara, Y.; Inagi, R.; Saito, A.; Destrihou, C. V.; Kurokawa, K. Mechanism of the Inhibitory Effect of OPB-9195 [(±)-2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation End-Product and Advanced Lipoxidation End-Product Formation. J. Am. Soc. Nephrol. 2000, 11, 1719-1725.
41. (a) Cunningham, J. J. The Glucose/Insulin System and Vitamin C: Implications in Insulin-Dependent Diabetes Mellitus. J. Am. Coll. Nutr. 1998, 17, 105-108.
42. (b) Tutuncu, N. B.; Bayraktar, M.; Varli, K. Reversal of Defective Nerve Conduction with Vitamin E Supplementation in Type 2 Diabetes-A Preliminary Study. Diabetes Care 1998, 21, 1915-1918.
43. (a) Tsuchida, K.; Nakamura, S.; Fujii, W.; Atsumi, T.; Kawata, T.; Makita, Z.; Koike, T. Decrease of TGF-Beta and Type-IV Collagen Production in Diabetic Nephropathy by a Novel AGE Inhibitor OPB-9195. Diabetes 1998, 47 (Iss. S1), 503.
44. (b) Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced Glycation End-Products: a Review. Diabetologia 2001, 44, 129-146.
45. Demopoulos, V. J.; Rekka, E. Isomeric Benzoylpyrroleacetic Acids: Some Structural Aspects for Aldose Reductase Inhibitory and Antiinflammatory Activities. J. Pharm. Sci. 1995, 84, 79-82.
46. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged Molecules for Protein Binding Identified from NMR-Based Screening. J. Med. Chem. 2000, 43, 3443-3447.
47. Lehuédé, J.; Fauconneau, B.; Barrier, L.; Ourakow, M.; Piriou, A.; Vierfond, J-M. Synthesis and Antioxidant Activity of new Tetraarylpyrroles. Eur. J. Med. Chem. 1999, 34, 991-996.
48. Roberfroid, M. B.; Viehe, H. G.; Remacle, J. Free Radicals in Drug Research. In Advances in Drug Research; Testa, B., Ed.; Academic Press Limited: London, 1987; vol. 16; pp 15-19.
49. (a) Nicolaou, I.; Demopoulos, V. J. A Study of the Friedel-Crafts Acylation of 1-Benzenesulfonyl-1H-pyrrole in the Preparation of 3-Aroylpyrroles. J. Heterocycl. Chem. 1998, 35, 1345-1348.
50. (b) Greenhouse, R.; Ramrez, C.; Muchowski, J. M. Synthesis of Alkylpyrroles by the Sodium Borohydride Reduction of Acylpyrroles. J. Org. Chem. 1985, 50, 2961-2965.
51. (c) Ketcha, D. M.; Gribble, G. W. A Convenient Synthesis of 3-Acylindoles via Friedel-Crafts Acylation of 1-(Phenylsulfonyl)indole. A New Route to Pyridocarbazole-5,11-quinones and Ellipticine. J. Org. Chem. 1985, 50, 5451-5457.
52. Entwistle, I. D.; Jackson, A. E.; Johnstone, A. W.; Telford, R. P. Reduction of Nitro-Compounds. J. Chem. Soc., Perkins Trans. 1 1977, 443-447.
53. Tembo, O. N.; Dallemagne, P.; Rault, S.; Robba, M. An Efficient Synthesis of New Phenylpyrrolizine and Phenylpyrrolopyrazine Derivatives. Heterocycles 1993, 36, 2129-2137.
54. Leysen, F. Y.; Ottenheijm, H. C. J. A Facile Synthesis of N-Substituted Pyrroles. Synth. Commun. 1995, 25, 1857-1861.
55. Cardinaud, I.; Gueiffier, A.; Debouzy, J-C.; Milhared, J-C.; Chapat, J-P. Synthesis of Pyrroloquinoline and Pyrrolonaphthiridine by an Intramolecular Cyclisation Reaction. Heterocycles 1993, 36, 2513-2522.
56. Chan, T. H.; Lee, S. D. 1,4-Dichloro-1,4-dimethoxybutane as a Mild Reagent for the Conversion of Primary Amines to Pyrroles. Synthesis of a Pyrrole Compound from Tobacco. J. Org. Chem. 1983, 48, 3059-3061.
57. (a) Dunn, J. P.; Ackerman, N. A.; Tomolonis, A. J. Analgetic and Antiinflammatory 7-Aroylbenzofuran-5-ylacetic Acids and 7-Aroyl-benzothiophene-5-ylacetic Acids. J. Med. Chem. 1986, 29, 2326-2329.
58. (b) Zaher, N; Nicolaou, I; Demopoulos, V. J. Pyrrolylbenzothiazole Derivatives as Aldose Reductase Inhibitors. J. Enzyme Inhib. Med. Chem. 2002, 17, 131-135.
59. Cadamuro, S.; Degani, I.; Dagnera, S.; Fachi, R.; Gatti. A.; Piscopo. L. General Methods for Synthesizing 2,4-Diacylpyrroles and their Precursors Containing One or Two Masked Acyl Groups. J. Chem. Soc., Perkin Trans. 1 1993, 273-283.
60. 3. J. Org. Chem. 1986, 51, 3038-3043.
61. Bell, Malcolm Rie (Sterling Drug Inc.) Ger. Offen. 1908541 (Cl. C 07d, A 61k), 18 Sep 1969, US Appl. Feb 1968; 1-(Carboxyalkyl)indoles. Chem. Abstr. 1970, 72, 66807m.
62. McOmie, J. F.; Watts, M. L.; West, D. E. Demethylation of Aryl Methyl Ethers by Boron Tribromide. Tetrahedron 1968, 24, 2289-2292.
63. Olah, G. A.; Narany, S. C.; Gupta, B. J. B.; Mulhotra, R. Synthetic Methods and Reactions. Transformations with Chlorotrimethylsilane/Sodium Iodide, a Convenient in situ Iodotrimethylsilane Reagent. J. Org. Chem. 1979, 44, 1247-1251.
64. Anagnostou, C.; Nicolaou, I.; Demopoulos, V. J. Synthesis of [5-(4-Pyrrol-1-yl-benzoyl)-1H-pyrrol-2-yl)]-acetic Acid and In Vitro Study of its Inhibitory Activity on Aldose Reductase Enzyme and on Protein Glycation. Pharmazie 2002, 57, 535-537.
65. Gui, T.; Tanimoto, T.; Kokai, Y.; Nishimura, C. Presence of a Closely-Related Subgroup in the Aldo-Ketoreductase Family of the Mouse. Eur. J. Biochem. 1995, 227, 448-453.
66. Del Corso, A.; Costantino, L; Rastelli, G.; Buono, F.; Mura, U. Aldose Reductase does Catalyse the Reduction of Glyceraldehyde through a Stoichiometric Oxidation of NADPH. Exp. Eye Res. 2000, 71, 515-521.
67. (a) Sestanj, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Duquesne, N.; Dvornik, D. N-[[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]-N-methylglycine (Tolrestat), a Potent, Orally Active Aldose Reductase Inhibitor. J. Med. Chem. 1984, 27, 255-256.
68. (b) Terashima, H.; Hama, K.; Yamamoto, R.; Tsuboshima, M.; Kikkawa, R.; Hatanaka, I.; Shigeta, Y. Effects of a New Aldose Reductase Inhibitor on Various Tissues In Vitro. J. Pharmacol. Exp. Ther. 1984, 229, 226-230.
69. (c) Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel. T. W.; Singleton. D. H. Novel Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic Acid (Zopolrestat) and Congeners. J. Med. Chem. 1991, 34, 108-122.
70. (d) Oka, M.; Matsumoto, Y.; Sugiyama, S.; Tsuruta. N.; Matsushima. M. A Potent Aldose Reductase Inhibitor, (2S,4S)-6-Fluoro-2′,5′-dioxospiro[chroman-4,4′- imidazolidine]-2-carboxamide (Fidarestat): Its Absolute Configuraton and Interactions with the Aldose Reductase by X-ray Crystallography. J. Med. Chem. 2000, 43, 2479-2483.
71. ClogP Version 4.72, Daylight Chemical Information Systems Inc., (http://www.daylight.com/).
72. Katritzky, A. R. Handbook of Heterocyclic Chemistry; Pergamon Press: Oxford, 1985; pp 76-79.
73. SPARTAN SGI Version 5.1.3 OpenGL, Wavefunction, Inc., 18401 Von Karman Avenue, Suite 370, Irvine, CA 92612.
74. Llorens, O.; Perez, J. J. Toward the Design of Chemical Libraries for Mass Screening Biased against Mutagenic Compounds. J. Med. Chem. 2001, 44, 2793-2804.